Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies - PubMed
5 hours ago
- #asthma
- #CRSwNP
- #biologics
- Severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are comorbidities linked by Type 2 inflammation.
- Biologics like dupilumab, mepolizumab, benralizumab, omalizumab, and tezepelumab are evaluated for dual clinical remission.
- A new composite definition for dual remission includes zero exacerbations/oral corticosteroids use and significant sinonasal improvement.
- Dupilumab is superior for sinonasal-dominant phenotypes, especially for olfactory recovery.
- Anti-IL-5 agents are better for exacerbation-dominant eosinophilic phenotypes.
- Tezepelumab shows promise for broad epithelial blockade based on the WAYPOINT trial.
- A biomarker-guided approach (FeNO, blood eosinophils, IgE) is recommended for stratified treatment.